« STWA, Inc. (ZERO) Enters LOI for Integration of AOT™ Technology into $2.5B Pipeline Project
Net Element, Inc. (NETE) is “One to Watch” »
Neuralstem, Inc. (CUR) Shows Solid Progress in Spinal Cord Neural Stem Cell Trial for ALS, Advancing Winning Platform for CNS Conditions

Today, Neuralstem, developers of a revolutionary platform of patented technologies for the production of neural stem cell lines and cell therapies, reported dosing of the fourteenth patient in its ongoing Phase I clinical trialing of the company’s spinal cord neural stem cells in ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease), marking the second patient to receive cells in the cervical (upper back) region of the spine and the trial’s first female patient. This is the first FDA-approved neural stem cell trial for the treatment of ALS.